LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395 Phase 3 COMPLETED

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	200
Start date	2002-07
Completion	2005-10

Conditions

• Diabetic Neuropathies
• Diabetes Mellitus, Insulin-Dependent
• Diabetes Mellitus, Non-Insulin-Dependent

Interventions

• Ruboxistaurin mesylate

Primary outcomes

• Reduction in neuropathic symptoms

Countries

United States, Australia, Belgium, Denmark, Estonia, Germany, Hungary, Israel, Spain